From physiopathology to treatment of Alzheimer's disease;De la physiopathologie au traitement de la maladie d'Alzheimer

Revue Neurologique

Volumn 162, Issue 10, 2006, Pages 909-912

  Delacourte, Andre ^a  

^a INSERM   (France)

Author keywords

APP; Dementia; Neurodegeneration; Tau; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CONFERENCE PAPER; GENE FUNCTION; GENE MUTATION; HUMAN; MOLECULAR DYNAMICS; NEOCORTEX; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN FUNCTION;

EID: 33749361480     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(06)75099-8     Document Type: Conference Paper

References (21)

1. BUEE L, BUSSIERE T, BUEE-SCHERRER V, DELACOURTE A, HOF PR. (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev, 33: 95-130.
2. CASAS C, SERGEANT N, ITIER JM et al. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol, 165: 1289-1300.
3. DELACOURTE A. (2006). Amyloid precursor protein neurotrophic properties as a target to cure Alzheimer's disease. European Neurological Disease, 29-30.
4. DELACOURTE A, BUEE L (2005). Modélisation de la maladie d'Alzheimer : un parcours semé d'embûches [Animal models of Alzheimer's disease : a road full of pitfalls]. Psychol Neuropsychiatr Vieil, 3 : 261-270.
5. DELACOURTE A, SERGEANT N, CHAMPAIN D et al. (2002). Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology, 59: 398-407.
6. DELACOURTE A, DAVID JP, SERGEANT N. (1999). The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology, 52: 1158-1165.
7. DOMINGUEZ D, TOURNOY J, HARTMANN D et al. (2005). Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem, 280: 30797-30806.
8. ENGEL T, HERNANDEZ F, AVILA J, LUCAS JJ. (2006). Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci, 26: 5083-5090.
9. GERVAIS F, PAQUETTE J, MORISSETTE C et al. (2006) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging.
10. GILMAN S, KOLLER M, BLACK RS et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64: 1553-1562.
11. GOEDERT M. (2005). Tau gene mutations and their effects. Mov Disord, 20: S45-52.
12. HARDY J. (1997). The Alzheimer family of diseases: many etiologies, one pathogenesis? . Proc Natl Acad Sci USA, 94: 2095-2097.
13. HARDY J, SELKOE DJ. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297: 353-356.
14. MARJAUX E, HARTMANN D, DE STROOPER B. (2004). Presenilins in memory, Alzheimer's disease, and therapy. Neuron, 42: 189-192.
15. REZAI-ZADEH K, SHYTLE D, SUN N et al. (2005). Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci, 25: 8807-8814.
16. ROVELET-LECRUX A, HANNEQUIN D, RAUX G et al. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet, 38: 24-26.
17. SELKOE DJ. (2000). The origins of Alzheimer disease: a is for amyloid. Jama, 283: 1615-1617.
18. SERGEANT N, DAVID JP, CHAMPAIN D, GHESTEM A, WATTEZ A, DELACOURTE A. (2002) Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J Neurochem, 81: 663-672.
19. ST GEORGE-HYSLOP P. (1995). Genetic determinants of Alzheimer disease. Prog Clin Biol Res, 393: 139-145.
20. TURNER PR, O'CONNOR K, TATE WP, ABRAHAM WC. (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol, 70: 1-32.
21. VON ROTZ RC, KOHLI BM, BOSSET J et al. (2004). The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J Cell Sci, 117: 4435-4448.